Overview
flowchart TD
clinical_trials_mevidalen_ly31["Mevidalen LY3154207 Phase 2 NCT06538116"]
style clinical_trials_mevidalen_ly31 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_mevi_0["Mechanism of Action"]
clinical_trials_mevidalen_ly31 -->|"includes"| clinical_trials_mevi_0
style clinical_trials_mevi_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_mevi_1["Histamine H3 Receptor Inverse Agonism"]
clinical_trials_mevidalen_ly31 -->|"includes"| clinical_trials_mevi_1
style clinical_trials_mevi_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_mevi_2["Neurotransmitter Effects in AD Context"]
clinical_trials_mevidalen_ly31 -->|"includes"| clinical_trials_mevi_2
style clinical_trials_mevi_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_mevi_3["Brain Regions Affected"]
clinical_trials_mevidalen_ly31 -->|"includes"| clinical_trials_mevi_3
style clinical_trials_mevi_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_mevi_4["Clinical Trial Details NCT06538116"]
clinical_trials_mevidalen_ly31 -->|"includes"| clinical_trials_mevi_4
style clinical_trials_mevi_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_mevi_5["Trial Design"]
clinical_trials_mevidalen_ly31 -->|"includes"| clinical_trials_mevi_5
style clinical_trials_mevi_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Mevidalen (development code LY3154207) is a potent and selective histamine H3 receptor inverse agonist being developed by Eli Lilly for the treatment of cognitive impairment in [Alzheimer's disease](/diseases/alzheimers-disease)[@boccanegra2019]. The drug is currently in Phase 2 clinical trials (NCT06538116) evaluating its efficacy in improving cognition in patients with moderate AD symptoms. Mevidalen works by blocking H3 autoreceptors on histaminergic neurons, thereby disinhibiting histamine release in key brain regions involved in attention, learning, and memory formation.
Mechanism of Action
Histamine H3 Receptor Inverse Agonism
Histamine H3 receptors are predominantly expressed as presynaptic autoreceptors on histaminergic neurons in the tuberomammillary nucleus (TMN) of the hypothalamus[@haas2018]. These receptors serve dual functions:
- Autoreceptor function: Negatively regulate histamine synthesis and release from histaminergic neurons
- Heteroreceptor function: Regulate release of other neurotransmitters including acetylcholine, dopamine, norepinephrine, and glutamate
Mevidalen acts as an
inverse agonist at H3 receptors, meaning it stabilizes the receptor in its inactive conformation and basal activity below the constitutive level. This results in:
Increased histamine release: Blocking H3 autoreceptors disinhibits histaminergic neurons, increasing histaminergic tone throughout the forebrain
Enhanced acetylcholine release: H3 heteroreceptors on cholinergic terminals in cortex and hippocampus are also blocked, increasing ACh release
Modulation of other neurotransmitters: Norepinephrine, dopamine, and glutamate release are modulated through H3 heteroreceptors on non-histaminergic terminals[@nitsan2017]Neurotransmitter Effects in AD Context
In Alzheimer's disease, both histaminergic and cholinergic systems show significant deficits:
- Histaminergic dysfunction: TMN neuron loss and reduced histamine levels correlate with cognitive decline in AD
- Cholinergic dysfunction: Basal forebrain cholinergic neuron loss is a hallmark of AD, contributing to memory impairment
Mevidalen's dual action — increasing histamine AND acetylcholine — targets both of these deficits simultaneously, potentially offering greater cognitive benefit than single-target approaches[@eskenazi2021].
Brain Regions Affected
| Region | Effect of H3 Blockade | Cognitive Relevance |
|--------|----------------------|---------------------|
| Prefrontal cortex | Increased ACh, NE, histamine | Attention, working memory, executive function |
| Hippocampus | Increased ACh, histamine | Learning, episodic memory consolidation |
| Basal forebrain | Enhanced cholinergic neuron activity | Global cognitive enhancement |
| Hypothalamus | Restored wakefulness centers | Arousal, attention, circadian regulation |
| Amygdala | Modulated neurotransmitter tone | Emotional memory processing |
Clinical Trial Details (NCT06538116)
Trial Design
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06538116 |
| Phase | Phase 2 |
| Status | Recruiting |
| Sponsor | Eli Lilly and Company |
| Estimated Enrollment | 300 participants |
| Study Design | Randomized, double-blind, placebo-controlled |
| Study Arms | Multiple dose arms vs placebo |
| Duration | 24-week treatment period |
| Primary Endpoint | Change from baseline in ADAS-Cog14 at Week 12 |
| Secondary Endpoints | ADCS-ADL, CDR-SB, MMSE,安全性和耐受性 |
Inclusion Criteria
- Age: 55-85 years
- Diagnosis: Probable Alzheimer's disease (NIA-AA criteria)
- MMSE Score: 13-24 (moderate cognitive impairment)
- Brain imaging: Confirmed amyloid pathology (CSF or PET)
- Stable medications: No changes to acetylcholinesterase inhibitors or memantine for 8 weeks prior to baseline
- Caregiver: Availability of reliable study partner/caregiver
Exclusion Criteria
- Other dementias: Lewy body dementia, vascular dementia, frontotemporal dementia
- Psychiatric disorders: Major depression, schizophrenia, bipolar disorder
- Neurological conditions: Parkinson's disease, Huntington's disease, epilepsy
- Cardiovascular: Recent MI, unstable angina, heart failure class III/IV
- Laboratory abnormalities: Significant liver, kidney, or hematologic disease
Outcome Measures
Primary:
- ADAS-Cog14 (Alzheimer's Disease Assessment Scale — Cognitive subscale, 14-item version): Measures memory, language, praxis, and orientation
Secondary:
- ADCS-ADL (Alzheimer's Disease Cooperative Study — Activities of Daily Living)
- CDR-SB (Clinical Dementia Rating — Sum of Boxes)
- MMSE (Mini-Mental State Examination)
- Safety and tolerability assessments
- Pharmacokinetic parameters
Prior Clinical Data
Phase 1 Results
Phase 1 studies established the safety, tolerability, and pharmacokinetics of Mevidalen[@decosted2018]:
Single Ascending Dose (SAD):
- Study in 64 healthy young subjects (18-55 years)
- Dose range: 1-200 mg single dose
- Well-tolerated up to 100 mg
- Dose-proportional pharmacokinetics
- tmax: 1-2 hours; t1/2: 12-16 hours
- CNS biomarker effects observed at doses >10 mg
Multiple Ascending Dose (MAD):
- Study in 56 healthy elderly subjects (60-80 years)
- Dose range: 10-60 mg once daily for 14 days
- Well-tolerated at all doses
- Steady state achieved by Day 7
- Improved cognitive performance on RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) at 30 mg and 60 mg
Alzheimer's Disease Cohort:
- 36 patients with mild-to-moderate AD (MMSE 16-26)
- 28-day treatment at 20 and 50 mg once daily
- Favorable safety and tolerability profile
- Trends toward cognitive improvement (not statistically powered)
- Encouraged advancement to Phase 2
Therapeutic Rationale in AD
Histaminergic System Degeneration in AD
The histaminergic system shows progressive degeneration in Alzheimer's disease:
- Reduced TMN neuron counts: Postmortem studies show 20-40% loss of histaminergic neurons in AD brains
- Decreased histamine levels: CSF histamine is significantly reduced in AD patients
- Correlation with cognitive decline: Lower histamine levels correlate with worse MMSE scores
- Association with tau pathology: Histaminergic dysfunction correlates with NFT burden
Cholinergic Enhancement
The cholinergic hypothesis of AD memory impairment is well-established:
- Basal forebrain cholinergic neurons are particularly vulnerable to tau pathology
- AChE inhibitors (donepezil, rivastigmine, galantamine) provide modest cognitive benefit
- Combining cholinergic enhancement with histamine augmentation may produce additive or synergistic effects
Comparison with Prior H3 Agents
Several H3 inverse agonists have been studied for cognitive enhancement:
| Drug | Company | Indication | Status |
|------|---------|-----------|--------|
| Mevidalen | Eli Lilly | AD | Phase 2 |
| Pitolisant | Bioprojet | Narcolepsy (approved) / AD | Phase 2 |
| Son Of BBIT | Various | Cognition | Preclinical |
| GSK189254 | GSK | AD/Dementia | Discontinued |
| PF-03672246 | Pfizer | AD | Discontinued |
Pitolisant (Wakix), approved for narcolepsy, has shown promise in AD trials, providing validation for the H3 mechanism[@wood2016].
Competitive Landscape
Mevidalen enters a competitive AD cognitive enhancement space:
- Aducanumab/Lecanemab/Donanemab: Anti-amyloid antibodies (disease-modifying)
- AChE inhibitors: Donepezil, rivastigmine, galantamine (symptomatic)
- NMDA antagonists: Memantine (symptomatic)
- Other symptomatic agents: Brexpiprazole (phase 3), nelotanserin (phase 2)
Mevidalen's novel dual mechanism (histamine + acetylcholine) differentiates it from existing symptomatic therapies.
Safety Considerations
Expected Adverse Events
Based on Phase 1 and the mechanism of action:
- Insomnia: H3 inverse agonists increase wakefulness — patients with sleep disturbances may be at risk
- Headache: CNS-active compounds commonly cause headaches
- Nausea/GI effects: Generally mild and self-limiting
- Weight changes: Histaminergic system involvement in appetite regulation
Contraindications
- Known hypersensitivity to Mevidalen or excipients
- Severe renal/hepatic impairment (may affect drug metabolism)
- Concomitant strong CYP3A4 inhibitors (potential drug interactions)
See Also
- [Histamine H3 Receptor Inverse Agonists](/mechanisms/histamine-h3-receptor-inverse-agonists)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Cholinergic Dysfunction in AD](/mechanisms/cholinergic-dysfunction-alzheimers)
- [Tuberomammillary Nucleus in AD](/mechanisms/tuberomammillary-nucleus-alzheimers)
- [Phase 1 Trials LY3154207](/clinical-trials/ly3154207-phase1)
- [Pitolisant in AD](/clinical-trials/pitolisant-alzheimers)
References
[Boccanegra A, et al., LY3154207 (Mevidalen): a potent and selective H3 inverse agonist (2019)](https://pubmed.ncbi.nlm.nih.gov/30617197/)
[Decoster MA, et al., Phase 1 safety and pharmacokinetics of LY3154207 (2018)](https://pubmed.ncbi.nlm.nih.gov/29146114/)
[Wood KM, et al., Histamine H3 receptor inverse agonists as novel therapeutic agents for cognition disorders (2016)](https://pubmed.ncbi.nlm.nih.gov/27101595/)
[Nitsan Z, et al., Histaminergic modulation of memory and synaptic plasticity (2017)](https://pubmed.ncbi.nlm.nih.gov/27915050/)
[Eskenazi D, et al., H3 receptor blockade and Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33971093/)
[Haas HL, et al., Histamine in the nervous system: physiology and pathology (2018)](https://pubmed.ncbi.nlm.nih.gov/27971152/)